PharmAla Announces Changes to Board of Directors

Core Viewpoint - PharmAla Biotech Holdings Inc. announces changes to its Board of Directors, including the resignation of Dr. Malik Slassi and the appointment of Mr. Lennie Ryer, aiming to enhance the board's expertise as the company progresses in its development [1][2][3]. Company Overview - PharmAla Biotech Holdings Inc. is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, with a dual focus on alleviating the backlog of clinical-grade MDMA for trials and commercial sales, as well as developing novel drugs [4]. - The company is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [4]. Board Changes - Dr. Malik Slassi has resigned from the board effective February 9, 2026, after four years of support and insight during the company's early stages [2][3]. - Mr. Lennie Ryer, a seasoned financial executive with extensive experience in corporate finance and governance, has been appointed to the board, bringing valuable expertise as the company enters a new phase of development [3].